☆ 4.8 Article

Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses

LANCET (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial

Karim Ali et al.

Summary: This Canadian study explores the effectiveness of remdesivir as a treatment for COVID-19. The results show that remdesivir has a modest but significant impact on important outcomes for patients and healthcare systems, such as the need for mechanical ventilation.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2022)

添加到收藏夹

News Item Medicine, General & Internal

Nature does things well

[Anonymous]

EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)

添加到收藏夹

Article Medicine, General & Internal

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients

A. Jayk Bernal et al.

Summary: This study found that early treatment with molnupiravir reduced the risk of hospitalization or death in at-risk, unvaccinated adults with Covid-19.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients

R. L. Gottlieb et al.

Summary: In symptomatic, nonhospitalized high-risk Covid-19 patients, a 3-day course of remdesivir significantly reduced the risk of hospitalization or death compared to placebo, with acceptable safety profile.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Editorial Material Medicine, General & Internal

The Goldilocks Time for Remdesivir - Is Any Indication Just Right?

Emily L. Heil et al.

Summary: The world has been grappling with a severe pandemic caused by SARS-CoV-2 for the past two years. Imperfect vaccine uptake and ongoing emergence of variants suggest that SARS-CoV-2 may become endemic, necessitating continued need for early therapies to reduce risk and transmission.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Infectious Diseases

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader et al.

Summary: A study conducted in COVID-19 patients admitted to hospital and requiring oxygen support found that remdesivir did not show significant clinical benefits compared to standard care alone.

LANCET INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Medicine, General & Internal

Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results

Summary: The authors of the study reported the interim results of using four repurposed antiviral drugs (remdesivir, hydroxychloroquine, lopinavir, and interferon beta-1a) in hospitalized COVID-19 patients. The study showed that these drug regimens had little or no effect on overall mortality, initiation of ventilation, and duration of hospital stay.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Anil Gupta et al.

Summary: In this study, among nonhospitalized patients with symptomatic Covid-19, sotrovimab treatment significantly reduced the risk of disease progression leading to hospitalization or death compared to placebo. Patients receiving sotrovimab also had a lower rate of serious adverse events.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 A Randomized Trial

Andreas Barratt-Due et al.

Summary: A randomized controlled trial conducted in 23 hospitals in Norway found that remdesivir and hydroxychloroquine did not affect viral clearance in hospitalized COVID-19 patients. There was also no impact on mortality, degree of respiratory failure, or inflammatory variables.

ANNALS OF INTERNAL MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

M. Dougan et al.

Summary: In this phase 3 trial, the combination of bamlanivimab plus etesevimab was found to reduce the incidence of Covid-19-related hospitalization and death among high-risk ambulatory patients compared to placebo, and also accelerated the decline in SARS-CoV-2 viral load.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

M. P. O'Brien et al.

Summary: The study indicates that subcutaneous REGEN-COV can effectively prevent severe Covid-19 and reduce the duration of symptoms in individuals at high risk for infection due to household exposure to confirmed SARS-CoV-2 cases.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

The Magic of Randomization versus the Myth of Real-World Evidence

Rory Collins et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

Yeming Wang et al.

LANCET (2020)

添加到收藏夹

Article Medicine, General & Internal

Remdesivir for the Treatment of Covid-19-Final Report

John H. Beigel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

COVID-19 vaccine trials should seek worthwhile efficacy

Philip Krause et al.

LANCET (2020)

添加到收藏夹

Editorial Material Medicine, General & Internal

FDA Approval of Remdesivir - A Step in the Right Direction

Daniel Rubin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Editorial Material Oncology

Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care

R. Peto

BRITISH JOURNAL OF CANCER (2011)

添加到收藏夹

Article Medicine, General & Internal

Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials

O Abe et al.

LANCET (2005)

添加到收藏夹

Article Medicine, General & Internal

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials

O Abe et al.

LANCET (2005)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.